- Amylyx Pharmaceuticals recently completed enrollment in its pivotal Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, a 16-week, randomized, double-blind, placebo-controlled study in 78 adults following Roux-en-Y gastric bypass surgery.
- This milestone moves Amylyx closer to Phase 3 data for a first-in-class GLP-1 receptor antagonist in a condition with no FDA-approved therapies, highlighting a potentially important step in addressing an underserved metabolic disorder.
- We’ll now examine how completing enrollment in the LUCIDITY Phase 3 trial shapes Amylyx’s investment narrative and future opportunity.
This technology could replace computers: discover 24 stocks that are working to make quantum computing a reality.
Amylyx Pharmaceuticals Investment Narrative Recap
To own Amylyx today, you need to believe avexitide can become a first-in-class therapy for post bariatric hypoglycemia and eventually support a broader rare disease pipeline. Completing enrollment in the LUCIDITY Phase 3 trial is a key operational milestone, but the main near term catalyst remains the Q3 2026 topline data, while the biggest risk is that results do not confirm earlier reductions in severe hypoglycemic events.
The most directly relevant recent update is Amylyx’s March 3, 2026 earnings release, which highlighted a full year 2025 net loss of US$144.74 million and no current product revenue. Against that backdrop, LUCIDITY’s progress takes on added weight, because a successful readout could help shift the business from pure cash burn toward its first potential commercial asset and eventually support the GLP 1 antagonist and neurodegeneration programs.
Yet, while the trial is fully enrolled, investors still need to be aware that...
Read the full narrative on Amylyx Pharmaceuticals (it's free!)
Amylyx Pharmaceuticals' narrative projects $107.8 million revenue and $23.1 million earnings by 2029. This implies an earnings increase of about $167.8 million from -$144.7 million today.
Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 63% upside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts were already cautious, projecting only about US$46.5 million of revenue and US$9.3 million of earnings by 2029, and this new LUCIDITY milestone could either challenge or reinforce that more pessimistic view, so it is worth comparing these differing expectations before deciding which story you think is closer to reality.
Explore 3 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth over 3x more than the current price!
The Verdict Is Yours
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
- Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.
Searching For A Fresh Perspective?
Our top stock finds are flying under the radar-for now. Get in early:
- Uncover the next big thing with 30 elite penny stocks that balance risk and reward.
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com